

PATENT SPECIFICATION

(11) 1444980

1444980

- (21) Application No. 55224/73 (22) Filed 28 Nov. 1973
 (31) Convention Application No. 1850615 (32) Filed 28 Nov. 1972 in
 (33) Soviet Union (SU)
 (44) Complete Specification published 4 Aug. 1976
 (51) INT CL² A61K 31/395
 (52) Index at acceptance

A5B 27X 27Y 383 38Y 401 402 40Y 482 48Y 551 552
 55Y 575 576 57Y 616 61Y 77Y



- (72) Inventors MIKHAIL DAVIDOVICH MASHKOVSKY
 ROBERT GEORGIEVICH GLUSHKOV
 NATALIA IVANOVNA ANDREEVA
 ANATOLY BOESLAVOVICH SMULEVICH
 GRIGORY YAKOVLEVICH AURUTSKY and
 VALENTINA VASILIEVNA GROMOVA


(54) PSYCHOTROPIC MEDICINAL PREPARATION

(71) We, VSESOJUZNY NAUCHNO-
 ISSLEDOVATELSKY KHIMIKO-FAR-
 MATSEVICHESKY INSTITUT IMENI
 S. ORDZHONIKIDZE, of 7 ulitsa
 5 Zubovskaya, Moscow, Union of Soviet
 Socialist Republics, a Corporation organised
 and existing under the laws of the Union of
 Soviet Socialist Republics, do hereby declare
 the invention, for which we pray that a patent
 10 may be granted to us, and the method by
 which it is to be performed, to be particu-
 larly described in and by the following state-
 ment:—

This invention relates to a psychotropic
 15 medicinal preparation for the treatment of
 depressions and other psychic disorders.

At present there exist a great range of
 psychotropic and, inter alia, antidepressant,
 20 medicinal preparations such as desipramine
 and imipramine. However, although these
 known medicinal preparations exhibit a
 marked therapeutic effect, they produce some
 side effects such as dryness in the mouth,
 constipation and accommodation disturbances,
 25 which limit their application for certain
 categories of patients.

The present invention provides a pharma-
 ceutical preparation comprising a salt of 3 -
 30 methyl - 8 - methoxy - 3H, 1,2,5,6 - tetra-
 hydropyrazino - (1,2,3 - ab) - beta - carbo-
 line of formula:



where A is a pharmaceutically acceptable in-
 35 organic or organic acid, together with a
 pharmaceutical carrier or diluent.

The hydrochloride of the preparation accord-
 ing to the invention has been given a pro-
 visory name "Incazan".

The salt is an odourless white powder
 with a yellowish tint, has a bitter taste, is
 40 freely soluble in water, and has a molecular
 weight of 291.5 and a melting point of from
 305 to 308°C.

The bitartrate semihydrate of this com-
 45 pound is prepared as slightly yellowish cry-
 stals freely soluble in water, and has a mole-
 cular weight of 339 and a melting point of
 from 220 to 222°C.

The pharmaceutical carrier or diluent may
 be liquid or solid. Thus, when it is liquid
 50 the preparation may take the form of a solu-
 tion for injection comprising the active in-
 gredient together with sterile pyrogen-free
 water or an injectable oil. Alternatively, where
 the carrier is a liquid the preparation may
 55 comprise a solution or suspension of the active
 ingredient in the carrier together with one
 or more pharmaceutical adjuncts such as anti-
 oxidants, preservatives, colouring agents,
 sweetening agents, and thickening agents, thus
 60 the preparation may take the form of a linctus
 or syrup for oral administration. Where the
 carrier is a solid, the preparation may take
 the form of, for example, a tablet, pill or
 lozenge or may be contained in a gelatine
 65 capsule. Alternatively, the preparation may
 take the form of a suppository comprising the
 active ingredient together with a suppository
 base. Also, the preparation may take the form
 of a pressurized composition (i.e. a so-called
 70 "aerosol" composition) comprising the active
 ingredient dissolved or suspended in a
 liquefied gaseous propellant.

In accordance with a particular embodi-
 75 ment of the invention, the preparation accord-
 ing to the invention will be present in dosage
 unit form (which term is intended to include
 containers containing fixed amounts of the
 active ingredient for dissolution in a sterile

solvent). These dosage unit forms will suitably contain from 10 to 150, preferably from 25 to 50, milligrams of active ingredient.

For administration per os, the preparation may be manufactured in the form of tablets, wherein the carrier is a pharmaceutical filler such as lactose, starch and calcium stearate. The amount of the active ingredient in each tablet is preferably 0.025 gm.

For parenteral administration, the recommended form comprises as the carrier a pharmaceutical solvent, for example water, for injection. In this form the amount of the active ingredient is preferably from 0.0125 to 0.025 gm per dosage unit, and the aqueous solution employed preferably has a concentration of 1.25 percent by weight.

The pharmacological properties of the hydrochloride of the preparation according to the invention and of its other salts such as bitartrate semihydrate, are the same as those of other antidepressants. The preparation according to the invention promotes the central effect of amphetamine and 5-hydroxy-tryptophane, and the peripheral effects of adrenaline, phenylethylamine, tyramine, serotonin and tryptamine.

The preparation according to the invention mitigates the depressing effects of reserpine and tetrabenazine as well as the cateleptic activity of phenothiazine derivatives (meterazine). As well as possessing some properties characterizing the known antidepressants such as imipramine and desipramine, the preparation according to the invention also possesses some distinctive characteristics, i.e. it produces no cholinergic effect nor does it promote the soporific effect of Hexenal, nor the analgesic effect of Promedol nor the local-anesthetic activity of Novocaine.

The preparation imipramine according to the invention in promoting the effects of phenylethylamine, tyramine and tryptamine. Biochemical investigations indicate that the preparation according to the invention when administered in doses sufficient to produce a marked therapeutic effect moderately inhibits monoaminoxidase activity only in the tissues of the kidneys, which indicates that its pharmacological effect is not based on antimonoaminoxidase action.

The toxicity of the active ingredient of the preparation according to the invention is quite low. Thus, the LD₅₀ of the preparation administered per os to mice is 445 mgm/kg.

Toxicological investigations on the preparation according to the invention on mice, rats and rabbits using single and multiple (during one month) doses have revealed that in amounts exceeding the clinically recommended doses by 30 to 50 times the preparation has no toxic effect on the animals.

The preparation according to the invention was tested in the treatment of depressive

states on 46 patients (13 men and 33 women). 33 patients were hospitalized and 13 were treated as outpatients. The age structure of the group at the time of treatment was as follows: 2 patients below 21 years of age; 20 patients from 21 to 30; 10 patients from 31 to 40; 11 patients from 41 to 50; and 3 patients above 50. By nosological forms, the patients were classified as follows:—

	subjects	
1. Schizophrenia	40	75
including recurrent	1	
shift-like	30	
sluggish	9	
2. Maniac-depressive psychosis	4	80
3. reactive depressions	2	

The preparation was given in 25-mgm tablets once or twice a day (in the morning and evening). The average daily dose was from 25 mgm to 150 mgm depending on the depth and structure of a particular depression. The duration of the course was from 1 to 2 weeks to 4 months.

As a result of the treatment, depression symptoms totally disappeared in 14 patients and were mitigated in another 18 patients. The therapeutic effect was the greatest in the patients whose depressive symptoms were associated with the disturbances of the anergic pole. The preparation according to the invention also proved effective in neurotic and hypochondriac depressions as well as in shallow depressions with delirium of depressive contents.

The patients with anxious depression were given the proposed preparation in small doses, 25 to 50 mgm per day (since large doses intensified the state of anxiety) in combination with sedatives such as Triphthasine and Sonapax.

The side effects of the preparation according to the invention were as follows: agitated depression — 1 case; intensified anxiety and anxious phobias — 3 cases; dermatitis — 2 cases; headache — 1 case. It should be noted that headache and dermatitis were transitory (without the preparation being withdrawn).


The clinical study of the preparation according to the invention leads to the conclusion that "Incazan" is an antidepressant recommendable for the treatment of sluggish, apathetic, adynamic, neurotic, hypochondriac and other depressive states.

Since it produces a few side effects, the medicinal preparation according to the invention may be recommended for the treatment of both hospitalized patients and outpatients. The preparation may be used in combination with neuroleptics, such as Triphthasine, Itaperazine and Sonapax. Itaperazine is a preparation described in the literature (see Handbook by M. D. Mashkovsky), and is 2 -

- 5 chloro - 10 - [3 - /I - (beta - hydroxy-ethyl) - piperazinyl - 4) - propyl] - phenothiazine dihydrochloride. Sonapax is another phenothiazine derivative, and is also described in the abovementioned Handbook, vol. I, p. 56.

WHAT WE CLAIM IS:—

- 10 1. A pharmaceutical preparation comprising a salt of 3 - methyl - 8 - methoxy - 3H, 1,2,5,6 - tetrahydropyrazino - (1,2,3 - ab) - beta - carboline of formula:



- 15 where A is a pharmaceutically acceptable inorganic or organic acid, together with a pharmaceutical carrier or diluent.
2. A preparation as claimed in Claim 1 in tablet form wherein the carrier is a pharmaceutical filler.
- 20 3. A preparation as claimed in Claim 2 wherein the filler is lactose, starch and calcium stearate.
4. A preparation as claimed in Claim 2 or

3 wherein there is 0.025 gm of the active ingredient in each tablet.

5. A preparation as claimed in Claim 1 wherein the carrier is a solvent for injection. 25

6. A preparation as claimed in Claim 5 wherein the amount of active ingredient is from 0.0125 to 0.025 gm per dosage unit. 30

7. A preparation as claimed in Claim 5 or 6, wherein the solvent is water.

8. A preparation as claimed in Claim 7 wherein the aqueous solution has a concentration of 1.25 percent by weight. 35

9. A preparation as claimed in Claim 1 in dosage unit form containing from 10 to 150 milligrams of the active ingredient.

10. A preparation as claimed in Claim 10 in dosage unit form containing from 25 to 50 milligrams of the active ingredient. 40

11. A pharmaceutical preparation according to Claim 1 substantially as herein described.

MARKS & CLERK,
Chartered Patent Agents,
Agents for the Applicant(s).

Reference has been directed in pursuance of section 9, subsection (1) of the Patents Act 1949, to Patent No. 1409935.